Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR) in skin cells, altering gene expression that regulates keratinocyte growth and differentiation. This leads to reduced epidermal hyperproliferation, normalization of skin shedding, and anti‑inflammatory effects that improve psoriatic lesions and keratinization abnormalities.

The appropriate dose of Neotigason is determined individually by a qualified prescriber based on the severity of the condition, patient weight, and laboratory monitoring. Physicians typically start with a low dose and adjust according to clinical response and safety parameters.

Acitretin is classified as pregnancy category X because it is highly teratogenic. It must not be used during pregnancy, and effective contraception is required for at least three years after the last dose. Use during breastfeeding is also discouraged due to potential risk to the infant.

To order Neotigason, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with traditional systemic agents such as methotrexate, acitretin offers a non‑immunosuppressive mechanism focused on keratinocyte regulation. Unlike biologics that target specific immune pathways, acitretin is oral, does not require injection, and may be preferred when immunosuppression is contraindicated, though it carries a higher risk of teratogenicity and lipid abnormalities.

Neotigason should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability and potency.

Neotigason is taken orally as a capsule with a full glass of water, usually with meals to reduce gastrointestinal discomfort. The exact timing and whether it is taken with food should follow the prescribing physician’s instructions.

The most serious risks include teratogenicity (birth defects), severe liver injury, marked hyperlipidemia, and pseudotumor cerebri (increased intracranial pressure). Patients should undergo regular laboratory monitoring and report any new headaches, visual changes, or signs of liver dysfunction promptly.

Neotigason is contraindicated in pregnant women, women planning pregnancy, and individuals who cannot maintain effective contraception for three years after stopping therapy. It should also be avoided in patients with severe hepatic impairment, uncontrolled hyperlipidemia, or pre‑existing bone disorders such as severe osteoporosis.